Fig. 2N clearly shows that the expression levels of CD276 in basal cell carcinoma and breast cancer were high; the ensuing specific analysis revealed that the expression of CD276 in fibroblasts in basal cell carcinoma was the highest, whereas its expression in melanocytes and fibroblasts in breast cancer was the strongest (Fig. 2O-T). This evidence concerns the gene CD276 and basal cell carcinoma.